FindTrial
Sign In

How Patients with Rare Pancreatic Tumors (SPEN) Do after Surgery: Survival, Recovery, and Complications

Clinical outcomes of Solid Pseudopapillary Epithelial Neoplasms (SPEN) of the Pancreas after Surgical Resection: A retrospective multicenter cohort study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/02/0102896
Enrollment
2000
Registered
2026-02-03
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C259- Malignant neoplasm of pancreas, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Tata Memorial Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All patients with final histology proven SPEN who underwent surgery. 2. The period for recruitment is January 2007 to Dec 2024 3. Patients who were deemed inoperable during surgical exploration will also be included in the study.

Exclusion criteria

Exclusion criteria: 1. Final histology not suggestive of SPEN 2. Date of surgery outside of study protocol 3. Incomplete case records

Design outcomes

Primary

MeasureTime frame
Overall survival and disease-free survival after surgical resection of SPEN.Timepoint: 5 years after surgery—

Secondary

MeasureTime frame
Short-term oncological results and postoperative complication rates.Timepoint: From date of surgery to 90 days post-surgery—

Countries

Australia, Bangladesh, China, Hong Kong, India, Italy, Japan, Malaysia, Nepal, New Zealand, Philippines, Republic of Korea, Singapore, Taiwan, Thailand, Viet Nam

Contacts

Public ContactDr Manish Bhandare

Tata Memorial Centre

manishbhandare@gmail.com07738389116

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026